Journey Medical Corp - Asset Resilience Ratio
Journey Medical Corp (DERM) has an Asset Resilience Ratio of 64.93% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2018)
This chart shows how Journey Medical Corp's Asset Resilience Ratio has changed over time. Check DERM strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Journey Medical Corp's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Journey Medical Corp.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $283.23 Million | 64.93% |
| Total Liquid Assets | $283.23 Million | 64.93% |
Asset Resilience Insights
- Very High Liquidity: Journey Medical Corp maintains exceptional liquid asset reserves at 64.93% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Journey Medical Corp Industry Peers by Asset Resilience Ratio
Compare Journey Medical Corp's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Shan Dong Dong-E E-Jiao Co Ltd
SHE:000423 |
Drug Manufacturers - Specialty & Generic | 20.44% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 48.48% |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535 |
Drug Manufacturers - Specialty & Generic | 11.69% |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773 |
Drug Manufacturers - Specialty & Generic | 4.31% |
|
Tibet Rhodiola Pharmaceutical Holding Co
SHG:600211 |
Drug Manufacturers - Specialty & Generic | 15.57% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550 |
Drug Manufacturers - Specialty & Generic | 18.70% |
Annual Asset Resilience Ratio for Journey Medical Corp (2014–2018)
The table below shows the annual Asset Resilience Ratio data for Journey Medical Corp.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 60.43% | $208.06 Million | $344.32 Million | +14.94pp |
| 2017-12-31 | 45.48% | $255.07 Million | $560.79 Million | -21.74pp |
| 2016-12-31 | 67.23% | $210.15 Million | $312.60 Million | +18.81pp |
| 2015-12-31 | 48.42% | $107.45 Million | $221.93 Million | +24.97pp |
| 2014-12-31 | 23.45% | $41.79 Million | $178.22 Million | -- |
About Journey Medical Corp
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat sev… Read more